Vol.1 Depressive, Anxiety, and Drug Abuse Disorders

Vol.1 Depressive, Anxiety, and Drug Abuse Disorders

Editors:Tomás Palomo, Trevor Archer

June 1994

Publisher: Editorial Complutense, Donoso Cortés, 65, 28015 MADRID

ISBN: 84-7491-503-1

Pages: 485

Vol.2 Schizophrenia, Movement Disorders, and Age Related Cognitive Disorders

Vol.2 Schizophrenia, Movement Disorders, and Age Related Cognitive Disorders

Editors:Tomás Palomo, Richard Beninger, Trevor Archer

June 1994

Publisher: Editorial Complutense, Donoso Cortés, 65, 28015 MADRID

ISBN: 84-7491-504-X

Pages: 434


International Meeting on Strategies for Studying CNS: Active Compounds: Models, Screens and Clinical Syndromes


April 26 - May 2 1992

The content of this congress, together with other contributions on the topic, are collected in vol. 1 and 2 of the series "Strategies for studying brain disorders".



  • G. Kenneth Lloyd, UK. GABAergic antidepressants
  • Steven F. Maier, USA. Models based on a learned helplessness hypothesis
  • Gerard Marek, USA. The DRL antidepressant screen
  • Gerald Curzon, UK. Freeding models relating to 5-HT agonista and antagonist
  • Paul Willner, UK. Stress and conflict: Behavioural symptoms related to depression
  • H. Christian Fibiger, Canada. Neuropharmacology of depresión


  • Sara Leibowitz, USA. Feeding disorders and depresión
  • Alfred Lewy, USA. Biological rhythms and depresión
  • Rutger van den Hoofdakker, The Netherlands. Antidepressant effects of sleep deprivation
  • PhilipW. Gold, USA. Neuroendocrinology of depression
  • F. Borsini, Italy. Behavioural despair syndrome
  • G. M. Goodwin, UK. SPECT and its use in depression

S3. Drug effects on social behaviour, aggression and anxiety

  • Berend Olivier, The Netherlands. Drugs, neurotrasmitters and offensive aggression
  • David Sanger, France. Suppression of social behavoiour and conditioned performance
  • Barry Everitt, USA. Motivation and performance in male sexual behaviour
  • Tom Insel, USA. Neuropeptides and maternal separation distress
  • J. Barret, USA. Anxiolytics
  • R. J. Blanchard, USA. Fear-defensive reactions

S4. Clinical etiology and treatment in relation to sex and aggression, depression and anxiety

  • Markuu Linnoila, USA. 5-HT and affective disorders
  • Donald Charney, USA. Serotonin anxiety and deppession
  • Charles Nemeroff, USA. Peptides: Affective disorders
  • J.F. William Deakin, UK. The 5-HT receptor imbalance theory of affective disturbance: Experimental test in humans
  • Athanatios Zis, Canada. On the mechanism of actino of E.C.T.: Neuroendocrine and brain microdialysis studies
  • E. de Souza, USA. Role of corticotropin-releasing factor in neuropsychiatric disorders
  • Joaquin del Rio, Spain. The posible role of serotonin receptor subtypes in psychiatric syndromes

S5. Opiates and psychostimulants

  • Robert Blaster, USA. Evaluation of pharmacoterapies for drug abuse treatment: Animals studies
  • Christina Spyraki, Greece. Neural basis of drug reinforcement
  • George Ricaute, USA. Substituted phenethylamine toxicity in animals and humans
  • John Woods, USA. Opiates
  • John Hughes, UK. Opiate receptors
  • Paolo Nencini, Italy. Interactions between opioids and stimulants

S6. Alcohol use and abuse

  • Charles O'Brien, USA. Efficacy of treatment of alcoholism
  • John Littleton, UK. Calcium antagonist and alcohol withdrawal
  • Boris Tabakoff, USA. Biochemical mechanisms of tolerance
  • Michael Shuckit, USA. Genetic studies of alcoholism
  • Edward Sellers, Canada. Serotonergic compounds in the treatment of alcoholism
  • E. Hárd, Sweden. Neonatal alcohol syndrome

S7. Abuse potencial of CNS drugs used therapeutically

  • Linda Dykstra, USA. CNS side effects of opiates
  • J. David Leander, USA. PCP-like NMDA antagonists: Clinical effects.
  • Cristina E. Johanson, USA. CNS side effects of benzodiazepines
  • Malcolm Lader, UK. Dependence aspects of anxiolytic drugs
  • Miguel Casas, Spain. Relevance of Dopamine systems in chemical addictions

S8. Animal models and drug screens in antipsychotic research

  • Sven Ahlenius, Sweden. Animal models and the evaluation of antipsychotic drugs
  • Brenda Costall, UK. Models of schizopsychotic disorders
  • Torgny H. Svensson, Sweden. Electrophysiology in the development of screens
  • Francis Colpaert, France. New concepts in the development of antipsychotic drugs
  • Lennart Heimer, USA. Perspectives on basal forebrain organization and psychotic disorders
  • L Creese, USA. DA receptors and drug action

S9. Clinical research into new antipsychotic drugs considering long-term therapeutic benefits and EPS

  • Tommy Lewander, Sweden. Remoxipride: Clinical profile
  • G. Sedwall, Sweden. PET scanning: D2 receptors and psychosis
  • R. Meibach, USA. Risperidone: Clinical profile
  • F. Kleinman, USA.The neuropathology of schizophrenia
  • T. G. Heffner, USA. New views on antipsychotic drugs
  • R. E. Pyke, USA. Thiosperone (BMY 1486): Clinical Results
  • Arvid Carlsson, Sweden. General aspects on the action of neuroleptic drugs

S10. Toxins that cause dísorders in animals

  • Irwin Kopin, USA. MPTP and neurodegeneration
  • M. Morelli, Italy. Priming of DA receptor supersensitivity
  • Alan R Crossman, UK. Excitatory amino acids in movement disorders
  • Justo García-Yébenes, Spain. Effects of growth factors on catecholamine cells
  • E. D. Abercombie, USA. Toxins that cause disorders in animals
  • Patrick McGeer, Canadá. Neurotransmitter turnover and endotoxic cell damage
  • R. Schwarcz, USA. Endogenous excitotoxins in neurodegenerative brain diseases

S11. Etiology and treatment of movement disorders such as Parkinson's dísease, Hungtingtons chorea and epilepsy

  • 0leh Hornykiewicz, Austria. Aging and cellular mechanisms of basal ganglia diseases
  • Sten-Magnus Aquilonius, Sweden. Parkinson's disease
  • Giuseppe Bartholini, France. Basal ganglia mechanisms involved in movement disorders
  • P. Groves, USA. Nigral striatal system in motor dysfunction
  • P. R Sanberg, USA. Huntington's chorea and cognitive disorders
  • A. Portera-Sánchez, Spain. Epidemiology and Etiology of parkisonism

S12. Brain mechanisms of learning processes and the assessment of efficacy of cognition enhancers

  • D. Price, USA. Non-human primates and trophic factors
  • John Harvey, USA. Effects of drugs on classical conditioning
  • D. Stephens, Germany. Benzodiazepines, O-carbolines and learning
  • D. Olton, USA. Theories of learning related to long-term and short-term memory
  • Ivan Izquierdo, Brazil. Brain BZ/GABA - A modulation of memory
  • N. White, Canada. Brain mechanisms in the assessment of cognitive enhancers
  • L. Cook, USA. Preclinical aspects of cognition enhancers

S13. Human syndromes which have as theír symptom the dísruption of memory and learning

  • José Luis López-Ibor, Spain. Current classification of Dementia
  • F. Growden, USA. Clinical features of Alzheimer's disease
  • M. J. de León, USA. Imaging analysis in Alzheimer's disease
  • B. Cordell, USA. Amyloidogenesis in Alzheimer's disease
  • E. K Warlington, UK. Semantic memory deficit in progressive degenerative disease
  • T. Douka, Germany. Clinical aspects of cognition enhancers
  • Vicky Chan-Palay, Switzerland. Depression and Dementia: Therapeutic strategies

Fundación Cerebro y Mente
c/ General Oraa, 47 - 1º E 28006 Madrid, España
Telf: +34 91 561 1267 Fax: +34 91 564 1817

Resolución mínima: 1024 x 768. Navegadores recomendados: Google Chrome / Firefox 3.5+ / Internet Explorer 9.0+ / Opera 9.0+ / Safari 3.0+